MARIBAVIR | TAKEDA PHARMS USA | ||
200MG | |||
No | No | ||
2032-Jan-04 | 2026-Nov-23 | ||
None | None | ||
None | No | ||
LIVTENCITY is a cytomegalovirus (CMV) pUL97 kinase inhibitor indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet. |
0 | 0 | 0 |
Total Other Developers | 5 |
---|
Drugs with Suitability | No |
---|
200MG | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com